Therapeutic potential of yeast killer toxin-like antibodies and mimotopes

Citations of this article
Mendeley users who have this article in their library.


This review focuses on the potential of yeast killer toxin (KT)-like antibodies (KTAbs), that mimic a wide-spectrum KT through interaction with specific cell wall receptors (KTR) and their molecular derivatives (killer mimotopes), as putative new tools for transdisease anti-infective therapy. KTAbs are produced during the course of experimental and natural infections caused by KTR-bearing micro-organisms. They have been produced by idiotypic vaccination with a KT-neutralizing mAb, also in their monoclonal and recombinant formats. KTAbs and KTAbs-derived mimotopes may exert a strong therapeutic activity against mucosal and systemic infections caused by eukaryotic and prokaryotic pathogenic agents, thus representing new potential wide-spectrum antibiotics. © 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.




Magliani, W., Conti, S., Salati, A., Vaccari, S., Ravanetti, L., Maffei, D. L., & Polonelli, L. (2004, October). Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Research.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free